With respect to chronic myeloid leukemia (CML), the 2018 annual meeting of the American Society of Hematology featured the following sessions: The CML educational session, 3 oral sessions with 6 abstract presentations each, and a long list of posters. This report will briefly summarize the key messages from the educational session discussing the choice of first-line treatment in CML patients. The highlights from the oral and poster sessions will be grouped in three categories: new drugs in CML, treatment-free remission (TFR) and CML and pregnancy.

(BELG J HEMATOL 2019;10(1):31–5)